• br Perspective AA LA and other PUFAs and

  2024-07-26

  

  Perspective AA, LA and other PUFAs and their lipid metabolites play an important role in human diseases. 12/15-LOX which is the metabolic enzyme of them plays an important role in the pathogenesis-related diseases such as atherosclerosis, diabetic nephropathy, neurological diseases and other path

• These mutations induce the gene auto activation in

  2024-07-26

  

  These mutations induce the gene auto-activation in 10–40% of adenocarcinomas, triggering the EGFR-signaling pathway in the absence of ligand. That leads to an uncontrolled acceleration of cell proliferation, survival and anti-apoptotic signals (Couraud et al., 2012). The frequency of these mutations

• br Methods br Results From a study population of

  2024-07-25

  

  Methods Results From a study population of 7069 patients, a total of 149 falls were reported during the study Alexidine dihydrochloride for an incidence rate (IR) of 5.2 falls per 1000 patient-days (PD), 95% confidence interval (CI) 4.4/1000 PD–6.1/1000 PD. The incidence rate ratio (IRR) for

• br Abbreviations br Acknowledgements This work was

  2024-07-25

  

  Abbreviations Acknowledgements This work was supported by grants from the National Institutes of Health (R01GM114168) and the Office of Naval Research (N000141210773) awarded to J.C·H and National Cancer Institute (5P30CA16059) Cancer Center Support Grant in support of Massey Cancer Center Pro

• br Introduction O Dowd et al identified a

  2024-07-25

  

  Introduction O’Dowd et al. identified a gene very similar to angiotensin type-1 receptor in 1993 (O’Dowd et al., 1993). The specific selective ligand of this receptor called APJ receptor was determined by Tatemoto et al. in 1998 as apelin (Tatemoto et al., 1998). The high expression of apelin and

• mlck mg br Diabetic retinopathy Diabetic retinopathy

  2024-07-25

  

  Diabetic retinopathy Diabetic retinopathy is a severe sight-threatening complication associated with diabetes mellitus. It is one of the most common causes of preventable blindness in the world. The risk of developing microvascular diabetic complications increases in diabetic patients with an inc

• br Small molecule homoisoflavonoid in combination with

  2024-07-25

  

  Small molecule homoisoflavonoid in combination with anti-VEGF therapy Basavarajappa et al. [11] reported a new synthetic homoisoflavonoid compound, SH-11037 by modifying the structure of naturally occurring homoisoflavonoid cremastranone. SH-11037 exhibited promising inhibition of human retinal m

• The excellent safety profile of solanezumab and encouraging

  2024-07-25

  

  The excellent safety profile of solanezumab and encouraging trends in the exploratory analyses in mild AD led to its inclusion in two secondary prevention trials, which are continuing in the hope that earlier intervention may yield more substantial benefit. The A4 study (NCT02008357) started in Febr

• Ultracentrifugation of AD brain was reported to remove of A

  2024-07-25

  

  Ultracentrifugation of AD CID 755673 was reported to remove >99.95% of Aβ, while only reducing seeding capacity by 70% (Langer et al., 2011). This suggests that the most potent seeding Aβ species are relatively small soluble oligomers rather than larger insoluble fibrils. It was also noted that thi

• Whereas allostery in the cell is relatively understudied sig

  2024-07-25

  

  Whereas allostery in the β cell is relatively understudied, significant progress has been made in understanding the physiology and mechanistic biology of how AMPK and its upstream kinases govern β cell function. LKB1 phosphorylates AMPKα at Thr172 [21], and loss of LKB1 in β cells abolishes phosphor

• Not all secondary metabolites or natural products

  2024-07-25

  

  Not all secondary metabolites or natural products can be fully synthesized due to their very complex structures that are too difficult and expensive on industrial scale. Hence, there is an urgent need to search for alternative remedies as naturally occurring biologically active secondary metabolites

• BET bromodomain inhibitor br Introduction AMPA receptors AMP

  2024-07-25

  

  Introduction AMPA receptors (AMPARs) mediate the majority of fast excitatory postsynaptic currents (EPSCs) in the BET bromodomain inhibitor (Jonas, 2000). The brevity of EPSCs and rapid deactivation of AMPARs depend upon a short lifetime of synaptically released glutamate, estimated to be about 1

• br Regulation of BCAA catabolism The BCAA catabolic system i

  2024-07-24

  

  Regulation of BCAA catabolism The BCAA catabolic system is equipped in mammalian cells to dispose of excess BCAAs, presumably resulting in relatively stable concentrations of BCAAs in blood and tissues in humans. The main BCAA catabolic pathway is localized in the mitochondria of all tissues. The

• Regarding A Rs and A ARs basal

  2024-07-24

  

  Regarding A1Rs and A2ARs, basal conditions generate a low tone of endogenous adenosine and cause A1R activation, in contrast to situations of increased adenosine where A2AR activation becomes dominant. When adenosine concentrations rise, e.g. during hypoxia, also time appears likely important in reg

• br A Rs which were

  2024-07-24

  

  A3Rs, which were cloned and then pharmacologically identified in the early 1990s, are expressed in multiple organs and peripheral tissues including ha tag involved in inflammatory responses (Gessi et al., 2008, Borea et al., 2014). While low levels are expressed in the CNS, A3R agonists produce f

15049 records 63/1004 page Previous Next First page 上5页 6162636465 下5页 Last page